RxDoctor Payments Data

Nicolette Chiesa, MD

Internal Medicine · Bridgeville, PANPI 1144292640

Payments from drug & device makers

$19,628in general payments, 2019–2025

Across 1,244 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AbbVie$2K
  • Pfizer$2K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Johnson & Johnson$1K
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$19,50999%
  • Education$1191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK157$2,517
AbbVie(2 entities)133$2,232
Pfizer126$1,847
Novo Nordisk127$1,621
AstraZeneca54$1,131
Johnson & Johnson78$1,112
Lilly USA, LLC57$956
E.r. Squibb & Sons, L.L.C.41$783
Takeda Pharmaceuticals U.S.A., Inc.46$776
Abbott51$636
Sanofi-aventis U.S. LLC40$610
Bayer37$559
Boehringer Ingelheim32$489
Amgen(2 entities)26$388
Merck26$385
Astellas Pharma US Inc25$356
Novartis21$310
Amarin Pharma, Inc.15$260
Biohaven Pharmaceuticals, Inc.15$215
Vanda Pharmaceuticals Inc.9$197
Biohaven Pharmaceutical Holding Company Ltd.13$191
Otsuka America Pharmaceutical, Inc.10$188
Exact Sciences6$114
Viatris Specialty LLC6$111
Phathom Pharmaceuticals, Inc.6$109
Teva Pharmaceuticals USA, Inc.6$102
Xeris Pharmaceuticals, Inc.4$86
Aimmune Therapeutics, Inc.4$81
Verona Pharma, Inc.3$69
Axsome Therapeutics, Inc.3$69
Azurity Pharmaceuticals, Inc.4$69
Esperion Therapeutics, Inc.4$68
Nestle Healthcare Nutrition Inc.3$66
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$66
Dexcom, Inc.4$62
Biogen3$60
Philips North America LLC4$57
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$56
Amneal Pharmaceuticals LLC2$53
Hikma Pharmaceuticals USA3$52
Mylan Specialty L.p.2$48
Pulmonx Corporation2$46
Electromed, Inc.4$46
Kowa Pharmaceuticals America, Inc.3$44
Medtronic2$39
Circassia Inc.2$29
Avanir Pharmaceuticals, Inc.2$28
Idorsia Pharmaceuticals US Inc2$28
Boston Scientific1$24
Neurelis, Inc.1$19
Sumitomo Pharma America, Inc.1$18
Sanofi Pasteur Inc.1$18
Daiichi Sankyo Inc.1$17
Avadel Specialty Pharmaceuticals, LLC1$17
Collegium Pharmaceutical, Inc.1$16
Sunovion Pharmaceuticals Inc.2$16
Corium, LLC1$16
MDD US Operations, LLC1$14
Sun Pharmaceutical Industries Inc.1$14
Eisai Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,628 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$86,936
Medicare patients
207
Services billed
2,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban170$141,061
JardianceEmpagliflozin73$80,860
Trelegy ElliptaFluticasone/Umeclidin/Vilanter120$79,973
JanuviaSitagliptin Phosphate52$53,290
OzempicSemaglutide36$36,317
FarxigaDapagliflozin Propanediol36$36,134
TradjentaLinagliptin34$29,313
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr45$28,926
MounjaroTirzepatide25$25,386
ProliaDenosumab13$22,106
EntrestoSacubitril/Valsartan19$21,904
TrulicityDulaglutide12$18,312
Breo ElliptaFluticasone/Vilanterol21$12,374
MyrbetriqMirabegron11$11,528
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$9,404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,847$141,061170 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$2,517$121,273186 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$489$119,576126 claims
MerckJanuvia, Janumet Xr$385$61,68263 claims
Lilly USA, LLCMounjaro, Trulicity$956$43,69837 claims
Novo NordiskOzempic$1,621$36,31736 claims
AstraZenecaFarxiga$1,131$36,13436 claims
AmgenProlia$388$22,10613 claims
NovartisEntresto$310$21,90419 claims
Astellas Pharma US IncMyrbetriq$356$11,52811 claims
AbbVieLinzess, Synthroid$2,232$9,87652 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$53$2,194248 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Bridgeville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →